Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 4th edition, 372 pages + the daily Top 10

Ovarian Neoplasms

Free Subscription 17.08.2020 1 BMC Cancer 1 Br J Cancer 1 Cancer 4 Gynecol Oncol 7 Histopathology 1 J Clin Oncol 1 J Natl Cancer Inst

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Cancer

1. EL ANSARI FZ, Jouali F, Marchoudi N, Bennani MM, et al
   Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC).
   BMC Cancer. 2020;20:747.
   PubMed         Abstract available
   
   

   
   Br J Cancer

2. YANG M, Zhang G, Wang Y, He M, et al
   Tumour-associated neutrophils orchestrate intratumoural IL-8-driven immune evasion through Jagged2 activation in ovarian cancer.
   Br J Cancer. 2020 Aug 11. pii: 10.1038/s41416-020-1026.
   PubMed         Abstract available
   
   

   
   Cancer

3. VYSOTSKAIA V, Kaseniit KE, Bucheit L, Ready K, et al
   Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
   Cancer. 2020;126:549-558.
   PubMed         Abstract available
   
   

   
   Gynecol Oncol

4. POTHURI B, O'Cearbhaill R, Eskander R, Armstrong D, et al
   Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
   Gynecol Oncol. 2020 Aug 7. pii: S0090-8258(20)33747.
   PubMed         Abstract available
   
   
5. POWELL CB, Laurent C, Ciaravino G, Garcia C, et al
   Streamlining genetic testing for women with ovarian cancer in a Northern California health care system.
   Gynecol Oncol. 2020 Aug 7. pii: S0090-8258(20)33662.
   PubMed         Abstract available
   
   
6. BEESLEY VL, Webber K, Nagle CM, DeFazio A, et al
   When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer.
   Gynecol Oncol. 2020 Aug 6. pii: S0090-8258(20)33664.
   PubMed         Abstract available
   
   
7. LEE EK, Xiong N, Cheng SC, Barry WT, et al
   Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
   Gynecol Oncol. 2020 Aug 5. pii: S0090-8258(20)33663.
   PubMed         Abstract available
   
   

   
   Histopathology

8. CASEY L, Singh N
   Metastases to the ovary arising from endometrial, cervical and fallopian tube cancer: recent advances.
   Histopathology. 2020;76:37-51.
   PubMed         Abstract available
   
   
9. RABBAN JT, Karnezis AN, Devine WP
   Practical roles for molecular diagnostic testing in ovarian adult granulosa cell tumour, Sertoli-Leydig cell tumour, microcystic stromal tumour and their mimics.
   Histopathology. 2020;76:11-24.
   PubMed         Abstract available
   
   
10. EUSCHER ED, Malpica A
    Gynaecological malignancies and sentinel lymph node mapping: an update.
    Histopathology. 2020;76:139-150.
    PubMed         Abstract available
    
    
11. BERNEY DM, Stoneham S, Arora R, Shamash J, et al
    Ovarian germ cell tumour classification: views from the testis.
    Histopathology. 2020;76:25-36.
    PubMed         Abstract available
    
    
12. VERMIJ L, Smit V, Nout R, Bosse T, et al
    Incorporation of molecular characteristics into endometrial cancer management.
    Histopathology. 2020;76:52-63.
    PubMed         Abstract available
    
    
13. MCCLUGGAGE WG
    Endometriosis-related pathology: a discussion of selected uncommon benign, premalignant and malignant lesions.
    Histopathology. 2020;76:76-92.
    PubMed         Abstract available
    
    
14. WILLIAMS AT, Ganesan R
    Role of the pathologist in assessing response to treatment of ovarian and endometrial cancers.
    Histopathology. 2020;76:93-101.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

15. TEW WP, Lacchetti C, Ellis A, Maxian K, et al
    PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
    J Clin Oncol. 2020 Aug 13:JCO2001924. doi: 10.1200/JCO.20.01924.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

16. LEE AW, Rosenzweig S, Wiensch A, Ramus SJ, et al
    Expanding our understanding of ovarian cancer risk: the role of incomplete pregnancies.
    J Natl Cancer Inst. 2020 Aug 7. pii: 5885090. doi: 10.1093.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: